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Abstract
Background: Chagas disease is a health threat for many people, mostly those living in Latin America. One of the
most important problems in treatment is the limitation of existing drugs. Prodigiosin, produced by Serratia
marcescens (Rhodnius prolixus endosymbiont), belongs to the red-pigmented bacterial prodiginine family, which
displays numerous biological activities, including antibacterial, antifungal, antiprotozoal, antimalarial,
immunosuppressive, and anticancer properties. Here we describe its effects on Trypanosoma cruzi mitochondria
belonging to Tc I and Tc II.
Results: Parasites exposed to prodigiosin altered the mitochondrial function and oxidative phosphorylation could
not have a normal course, probably by inhibition of complex III. Prodigiosin did not produce cytotoxic effects in
lymphocytes and Vero cells and has better effects than benznidazole. Our data suggest that the action of
prodigiosin on the parasites is mediated by mitochondrial structural and functional disruptions that could lead the
parasites to an apoptotic-like cell death process.
Conclusions: Here, we propose a potentially useful trypanocidal agent derived from knowledge of an important
aspect of the natural life cycle of the parasite: the vector-parasite interaction. Our results indicate that prodigiosin
could be a good candidate for the treatment of Chagas disease.
Background
Chagas disease continues to represent a health threat for
an estimated 28 million people, most of them living in
Latin America. One of the most important problems in
the outcome of Chagas disease is the limitation of exist-
ing drugs for treatment [1]. For more than 40 years,
only two drugs, nifurtimox and benznidazole, have been
available to treat Chagas disease. Both have limited effi-
cacy (about 80% efficacy in the acute phase and lower in
the chronic phase), as well as frequent and significant
side effects [2]. Other potentially beneficial drugs, such
as allopurinol or itraconazole, do not have a high
enough degree of clinical efficacy, as compared with
nifurtimox or benznidazole; Posaconazole is a promising
drug, but expensive [2]. Furthermore, hundreds of nat-
ural and synthetic compounds have been tested against
the protozoan parasite Trypanosoma cruzi, the causative
agent of Chagas disease. However, very few are devoid
o fc y t o t o x i ca c t i v i t yo rh a v ep r o v e dm o r ee f f i c a c i o u s
than nifurtimox and benznidazole, especially against the
intracellular amastigotes [3]. Therefore, disease control
is mainly based on the elimination of insect vectors.
Most species of the Triatominae (Hemiptera-Reduviidae)
subfamily are potential vectors of T. cruzi. It has been
reported that in the first few days after a blood meal,
the number of bacteria in the anterior midgut (stomach)
of Rhodnius prolixus increases dramatically. In addition,
many of the bloodstream trypomastigotes are lysed in
the vector’ss t o m a c h .T h i sp r o b a b l yo c c u r sa sp a r to fa
complex ecological interaction in the vector, where bac-
teria play a central role [4]. A wide variety of bacteria
including species from the Actinobacteria, Firmicutes,
and Proteobacteria have been detected in the triatomine
midgut tract [5,6]. It has been reported that Serratia
marcescens biotype A1a has trypanolytic activity in the
gut of the vector Rhodnius prolixus, especially on the Y
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could be responsible for the trypanocidal activity
observed in the vector.
Prodigiosins, which belong to the red-pigmented bac-
terial prodiginine family, are tripyrrolic compounds that
display numerous biological activities, including antibac-
terial, antifungal, antiprotozoal, antimalarial, immuno-
suppressive, and anticancer properties [8,9]. This broad
spectrum of activities might be related to their capacity
to alter key proteins involved in cell cycle or intracellu-
lar signal transduction or to induce apoptosis [10]. Cer-
tainly, there is abundant evidence indicating that
bacterial prodiginines and synthetic derivatives are effec-
tive proapoptotic agents with multiple cellular targets,
and they are active against numerous cancer cell lines,
including multidrug-resistant cells [9]. Very important is
the demonstration of little or no toxicity toward normal
cell lines. For this reason a synthetic derivative of prodi-
ginines, GX15-070 (Obatoclax), developed through
structure-activity relationship studies of the pyrrolic ring
A of GX15, is in multiple Phase I and II clinical trials in
both single- and dual-agent studies to treat different
types of cancer [8,11].
Therefore, prodiginines have real therapeutic potential
and although their mode of action is not yet clear and
can vary depending on cell type, it has been reported
that their effects can strongly compromise the mito-
chondrial metabolism. The mitochondrial disturbances
can be evidenced by alterations in cellular respiration,
energy balance, or even structural modifications on the
organelle as proposed recently [12-14]. All these altera-
tions suggest that the prodigiosin effects could result in
an apoptotic process on cells [13-15].
Here we provide data on the selective trypanocidal
activity of prodigiosin, evidenced by low cytotoxicity
against a normal cell line and human lymphocytes.
Additionally, we compare the effects of several mito-
chondrial electron transport chain (ETC) inhibitors, to
propose the mitochondria as a possible target for prodi-
giosin effects on T. cruzi.
Results
Trypanocidal activity of prodigiosin and electron
transport chain inhibitors
Axenic cultures of T. cruzi epimastigotes were treated
with different concentrations of rotenone, TTFA, KCN,
antimycin A, or prodigiosin for 24 h. Rotenone and
KCN had no effect on T. cruzi viability, while TTFA
and antimycin A decreased the viability by 60 and 50%,
respectively. Both parasite strains tested (SN-3 and AF-
1c7) had similar responses to mitochondrial inhibitors
(Figure 1). The activity of prodigiosin showed higher
trypanocidal activity than the other mitochondrial inhi-
bitors assayed. SN-3 and AF-1 c7 parasites showed a
small differential susceptibility to prodigiosin treatment.
SN-3 IC50 was 2.7 μM while AF1 c7 IC50 was 2.2 μM( p
<0 . 0 5 )( F i g u r e1 ) .T h eI C 50 to benznidazole was 34.62
and 4.69 to SN-3 and AF1. SN-3 trypomastigotes treated
with prodigiosin presented an IC50 of 3.2 μM, which is
slightly higher than epimastigote IC50 (Figure 2). The T.
cruzi AF-1 clone was unable to infect Vero cells. Thus,
the prodigiosin effect on trypomastigote viability against
this clone was not determined.
Cytotoxicity assay
To evaluate prodigiosin selectivity, Vero cells and
human lymphocytes were treated with different con-
centrations of the compound for 24 h. Indeed, as
observed in Figure 3, prodigiosin had a slightly toxic
effect on the viability of Vero cells, with IC50 6.49 ±
0.8 and a selectivity index (IC50 Vero cells/IC50 para-
s i t e s )o f2 . 2( S N 3 )a n d2 . 4 9( A F 1c 7 ) .H o w e v e r ,o n
human lymphocytes, the toxic effects of prodigiosin
Figure 1 Activity of prodigiosin against Trypanosoma cruzi
epimastigotes of the SN-3 strain and AF1 clone 7.2×
10
6epimastigotes were treated with different concentrations of
prodigiosin for 24 h and its viability was evaluated by flow
cytometry using propidium iodide.
Figure 2 Activity of prodigiosin against Trypanosoma cruzi
trypomastigotes of the SN-3 strain.2×1 0
6parasites were treated
with different concentrations of prodigiosin for 24 h and its viability
was evaluated by flow cytometry using propidium iodide.
Genes et al. Parasites & Vectors 2011, 4:66
http://www.parasitesandvectors.com/content/4/1/66
Page 2 of 8were minimal with less of 25% cell death at 6 times the
IC50 concentration (Figure 3).
Mitochondrial function assays
Effects on oxygen uptake
T os t u d yt h ep r o d i g i o s i ne f f e c t so no x y g e nu p t a k e ,w e
used the mitochondrial inhibitors TTFA and KCN as
controls. Table 1 shows the effects of TTFA, KCN, and
prodigiosin on oxygen uptake. KCN inhibited mitochon-
drial respiration by 50%, while prodigiosin and TTFA
inhibited parasite respiration by more than 80%. These
results indicate that the mitochondrial function is
altered and that oxidative phosphorylation does not take
a normal course. On the other hand, the addition of
duroquinol, but not succinate, to prodigiosin-treated
epimastigotes re-established and increased oxygen
uptake, indicating that inhibition of respiration in T.
cruzi could occur mainly due to the blockade of com-
plex III (Figure 4). No effect of DMSO alone, in which
prodigiosin was dissolved, was observed.
Mitochondrial transmembrane potential (Ψm)
measurements
We studied the Ψm through incorporation of the TMRM
probe, to determine whether the effects of prodigiosin on
T. cruzi mitochondria were associated with the metabolic
function of this organelle. We characterized the T. cruzi
Ψm using the classic mitochondrial inhibitors rotenone,
TTFA, KCN, and antimycin A. Subsequently, parasites
were incubated with TMRM after 1 h of treatment with
prodigiosin or mitochondrial inhibitors, and TMRM
fluorescence was measured by flow cytometry after 30
min of incubation. The uncoupler CCCP was used as
positive control. Our results show that both rotenone
and KCN have little effect on Ψm, while TTFA and anti-
mycin A decrease the Ψm after 1 h of treatment (Figure
5). Conversely, prodigiosin demonstrated a dose-depen-
dent membrane hyperpolarization. This hyperpolariza-
tion was similar in both the T. cruzi SN-3 strain and AF-
1 c 7 (data not shown), indicating that the mechanism of
action in both parasite strains is similar.
Discussion
Herein we report the activity of prodigiosin against T.
cruzi, and provide evidence that its mode of action
involves the mitochondrial function. Current therapy for
Chagas disease is not 100% effective. This picture is
complicated by the fact that nifurtimox and benznida-
zole produce a wide variety of adverse events that may
necessitate suspension of treatment. In addition, several
Figure 3 Activity of prodigiosin against Vero cells and human lymphocytes. 2.5 × 10
6 adherent Vero cells were treated with prodigiosin for
24 h. After incubation, the supernatant and the adherent cells, previously dislodged, were used to quantify live cells by propidium iodide. 2 ×
10
5 lymphocytes were treated with prodigiosin for 24 h. The lives cells were counting by optical microscopy using the trypan blue dye.
Table 1 Effect of prodigiosin, TTFA, and KCN on mitochondrial respiration.
Oxygen uptake Oxygen uptake after
succinate
Oxygen uptake after
duroquinol
Oxygen uptake after TMPD/
ascorbate
nmol O2 /min/mg protein nmol O2 /min/mg protein nmol O2 /min/mg protein nmol O2 /min/mg protein
Control 13.88889 ___ ___ ___
Prodigiosin (5 mM) 2.46667 2.46667 6.53333 44.66667
TTFA (5 mM) 2.23333 ND ND ND
KCN (5 mM) 6.76722 ND ND ND
Oxygen consumption was evaluated in control and treated parasites. In order to determine which complexes of the electron transport chain were involved in the
abnormal respiration, we added electron donors for each one of the complexes. The untreated parasites showed a higher oxygen uptake with respect to
prodigiosin TTFA- and KCN-treated parasites. However, when electron donors for complex II and III were added the oxygen uptake was increased.
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drugs [1].
Diverse approaches have been used to search for new
trypanocidal compounds, from natural and synthetic
sources. Here, we propose a potentially useful trypanoci-
dal agent that is derived from knowledge of an impor-
tant aspect of the natural life cycle of the parasite: the
vector-parasite interaction. Indeed, basic biological fac-
tors such as the food supply, intestinal components, gut
flora, and insect physiology, which are relevant to
understanding the parasite-vector interaction reveal new
perspectives for the control of Chagas disease. Although
Trypanosoma cruzi and triatomines probably did not
co-evolve to facilitate protozoan transmission [16], it is
clear that Chagas disease is dependent on a high degree
of interaction between the triatomine vectors and the
parasites.
The co-evolution of parasites and insects necessarily
promoted the development of strategies based on both
insect vector and parasite mechanisms, maintaining an
ecological equilibrium that might facilitate parasite
development in the invertebrate host. Multiple factors
are present in the insect vector gut that explain the
establishment of T. cruzi colonization. One outstanding
factor is the potential influence of the gut microbiota on
the parasite life cycle. In this respect, following a blood
meal, bacterial populations in the triatomines’ midgut
often undergo massive rapid expansions, as much as
10,000-fold [7]. Many microbial factors may be pro-
duced in the vector gut to target parasites ingested with
a blood meal. These include pigments such as prodigio-
sin that are produced by the Gram-negative bacteria S.
marcescens, S. plymuthica, and Streptomyces [17], all of
which occur in the midgut of vector insects. Prodigiosin
induces apoptotic phenomena and cell death in cancer
cell lines [18]. In addition, it has been reported to have
a strong inhibitory effect on a V79 fibroblast cell line
[19]. However, other studies failed to demonstrate cyto-
toxicity against normal cells as compared with tumor
cells lines [20]. In addition, prodigiosin derivatives show
marked activity against Plasmodium falciparum [21],
and strong activity against T. cruzi has also been
reported [19].
To study the mode of action of prodigiosin on T.
cruzi, we focused our research on the mitochondrial
function. T. cruzi has only one mitochondrium, which is
fundamental to parasite survival and regulation of the
processes related to energy balance and apoptosis mod-
ulation. We focused on two points in mitochondrial
metabolism. The first was oxygen consumption, a key
step in oxidative phosphorylation inside the mitochon-
drial matrix, and the second was the mitochondrial
membrane potential (Ψm). Ψm is crucial for ATP pro-
duction by ATP synthase, and it is also involved in pro-
tein transport inside the organelle and in regulation of
the glycolysis process. Moreover, its variations are used
as an earlier marker of mammalian and protozoan pro-
grammed cell death (PCD) progression.
In order to validate our experimental strategy, we stu-
died the effects of classic mitochondrial inhibitors. The
results showed that rotenone and KCN, electron trans-
port chain inhibitors of complex I and IV, respectively,
do not have an effect on T. cruzi viability, and caused
slight or no Ψm and cellular respiration alterations. Our
data confirm the results obtained by other groups sug-
gesting that T. cruzi complex I is absent or at least can-
not be inhibited by rotenone [22] and complex IV might
have an alternative pathway, probably mediated by a try-
panosome alternative oxidase as described for T. brucei
[23,24]. The existence of mitochondrial complex I in
trypanosomatids is still a matter of intense discussion.
Recently, a very detailed bioinformatic analysis to pre-
dict the composition of a putative trypanosomatid com-
plex I revealed the presence of all subunits known to be
Figure 5 Effect of prodigiosin on mitochondrial
transmembrane potential of epimastigotes of T. cruzi SN-3
strain. 1.5 × 10
6 parasites/mL were treated with rotenone, TTFA,
antimycin A, KCN, or prodigiosin for 1 h. The parasites were then
incubated with TMRM and analyzed with a cytometer. The
uncoupler CCCP (100 μM) was used as positive control. *MIF:
Medium intensity of fluorescence.
Figure 4 Effects of prodigiosin on mitochondrial electron
transport chain. Electron donators were added after the addition
of prodigiosin (0.287 μM to 5 mM) to the oxygen consumption
reaction mix, and oxygen uptake was determined.
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brane subunits assumed to be involved in proton extru-
sion are missing, suggesting that this complex is not
involved in energy transduction [25]. In this sense,
experimental data obtained in T. cruzi natural strains
containing deletions in the ND4, ND5 and ND7 genes
coding for complex I subunits demonstrated that this
complex is not functional in NADH oxidation and also
is not involved in energy transduction [26]. Further-
more, a RNAi study against the putative subunits of
complex I of T. brucei revealed the presence of this
complex and its participation in electron transport,
although this complex does not play an important role
in energy metabolism of the T. brucei procyclics [27].
Taking together, these results and those reported in this
study, indicate that the function of mitochondrial com-
plex I remain a very intriguing issue to be studied.
On the other hand, the treatment with TTFA, a succi-
nate dehydrogenase (complex II) inhibitor, was able to
induce considerable dysfunction of the T. cruzi mito-
chondria, which was evidenced by a decrease in mem-
brane depolarization, respiration and cell viability. It has
been suggested that the complex II in T. cruzi is the
main electron sink from the Krebs cycle and its impor-
tance in energy transduction is clear [22]. Similarly, the
treatment with the complex III inhibitor antimycin A
showed a similar effect to the TTFA, inducing a loss of
mitochondrial intermembrane potential and decreasing
respiration and cell viability. All of these results are in
concordance with previous reports showing the impor-
tance of complex II and III in the maintenance of mito-
chondrial stability in T. cruzi.
On the other hand, potassium cyanide was able to
induce the blockage of cellular respiration in at least
50% of oxygen uptake. Similar results have been
reported in other mitochondrial respiration studies
[28,29]. KCN treatment did not induce a decrease on
the Ψmo re v e no np a r a s i t ev i a b i l i t y .I th a sb e e ns u g -
gested that T. cruzi have three respiratory terminals: 1)
A respiratory terminal sensitive to cyanide and azide; 2)
a cyanide-sensitive but azide-insensitive terminal; and 3)
a terminal insensitive to both inhibitors.
Taking all the results obtained with the mitochondrial
electron transport chain inhibitors, we concluded that
the behavior and measurements made show the metho-
dology’s confidence in studying other different stimuli
such as prodigiosin.
The mitochondrial alterations observed during prodi-
giosin treatment included an important inhibition of
oxygen consumption, probably due to the action of pro-
digiosin throughout the electron transport chain. The
use of electron donators allowed us to propose that one
of the effects of prodigiosin inside T. cruzi mitochondria
could be associated to complex III blockage, although
complex II also presented a slight reactivation after suc-
cinate addition. To confirm our hypothesis we studied
the Ψm behavior. The Ψm is one of the most important
events inside the mitochondria of several cell types and
usually a decrease of Ψm is associated with PCD [30].
Furthermore, hyperpolarization has been identified as an
early event related with H2O2 [31], p53 [32], and staur-
osporin-induced apoptosis [33]. Due to Ψm hyperpolari-
zation and extrusion of H
+ ions from the mitochondrial
matrix, the cytochromes within the electron transport
chain become more reduced, which favors the genera-
tion of reactive oxygen intermediates (ROI). Thus, mito-
chondrial hyperpolarization is a likely cause of ROI
production at early stages, representing a key checkpoint
in cell-fate decision [34,35]. Indeed, prodigiosin induced
a marked hyperpolarization of the mitochondria after 1
h of treatment, suggesting that prodigiosin could act on
an early stage of an apoptotic-like cell death pathway.
All these results indicate that processes related to the
functional and structural stability of mitochondria in T.
cruzi are altered and could govern the success of pro-
grammed cell death pathways in prodigiosin-treated T.
cruzi parasites.
These findings are consistent with several reports
where the mode of action of prodigiosin is related to
mitochondrial alterations. The main effects include
modifications of oxygen uptake, ATP production, and
Ψm that conduce to cell death by an apoptotic process
[13]. Recently, an apoptotic cell death process was dis-
covered in protozoan parasites such as T. brucei, Leish-
mania sp,a n dT. cruzi [36-38]. In these organisms, the
pathways associated to apoptosis progression remain to
be elucidated, and the mitochondrial role is unclear;
however, some recent works suggest that disturbances
of this organelle can induce a similar mammalian apop-
totic phenotype [39-45].
T h u s ,w ep r o p o s et h a tt h ea n t i - T. cruzi prodigiosin
effect could be facilitated through an apoptotic-like phe-
nomenon mediated by induction of mitochondrial dys-
function, analogous to that reported for cancer cells
[13-15]. It is possible to speculate that the apoptotic
progression of epimastigotes inside the insect gut might
result in at least three different populations of virulent
feces (epimastigotes, trypomastigotes, and dead para-
sites). If the parasitic apoptotic population from the vec-
tor is capable of interacting with immune cells of the
vertebrate host, it is likely that the resulting attenuation
of the immune response might contribute to T. cruzi
evasion of the host immune response [46]. This would
thus facilitate Chagas disease progression [47], as pre-
viously demonstrated and suggested in Leishmania
infantum by Zandbergen et al. [48,49].
Finally, our results indicate that prodigiosin could be a
good candidate for the treatment of Chagas disease,
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benznidazole, demonstrating a lower IC50. Future
research is needed to clarify these findings and the role
of prodigiosin in mitochondrial complex III.
Conclusions
Our results indicate that prodigiosin could be a good
candidate for the treatment of Chagas disease. We com-
pared the activity of prodigiosin in two different lineages
of T. cruzi and both showed a low IC50,w h i c hi sl o w e r
than that of benznidazole. However, further research is
needed to address these issues and to confirm the
advantages of mitochondrial intermembrane potential
measurements as a crucial and useful indicator of the
biochemical status of kinetoplastid parasites.
Methods
Parasites
Trypanosoma cruzi epimastigotes of the SN-3 strain (TC
I) and AF-1 clone 7 (TC II), both obtained from triato-
mines, were cultured at 28°C in LIT medium supple-
mented with 10% FBS. Trypomastigote forms were
obtained from SN-3 strain-infected Vero cells and col-
lected from the culture media by centrifugation at 500 g
for 3 min. The supernatant was discarded and fresh
RPMI medium was added to the resultant pellet. Tubes
were incubated for 2 h to allow the trypomastigotes to
swim out of the pellet. The resulting suspension was
then centrifuged and the pellet was suspended in fetal
bovine serum-RPMI culture medium at a final density
of 2 × 10
7 trypomastigotes/mL.
Bacterial strain
Wild-type Serratia marcescens that produces prodigiosin
was donated from the School of Medicine, University of
Antioquia. S. marcescens was characterized using the
biochemical test API-20. The bacterial cultures were
maintained in nutritive agar for 24 h at 30°C.
Reagents and inhibitors
The electron transport chain inhibitors Rotenone (speci-
fic complex I inhibitor), 2-thenoyltrifluoroactone
-TTFA- (specific complex II inhibitor), antimycin A
(specific complex III inhibitor), potassium cyanide
-KCN- (specific complex IV inhibitor), the uncoupler
carbonyl cyanide 3-cholophenylhydrazone (CCCP), and
all other reagents used were from Sigma-Aldrich.
Prodigiosin isolation
Prodigiosin was extracted by S. marcescens lysis with a
mixture of methanol/1N HCl (24:1). After centrifugation
at 2000 g for 10 min, the solvent in supernatant was
removed using a rotary evaporator system. Atmospheric
pressure liquid chromatography of the extract was
performed on a silica gel with dichloromethane and
methanol as solvents. The eluted pigmented fractions
were pooled and the dichloromethane/methanol extract
was vacuum evaporated, redissolved in methanol, and
characterized by H-NMR.
Prodigiosin and inhibitors activity
Epimastigotes and trypomastigotes at a density of 2 ×
10
6 per mL were treated with different concentrations
of mitochondrial electron transport chain inhibitors or
prodigiosin for 24 h. Moreover, epimastigotes were
exposed to benznidazole with the aim of identifying the
IC50. Culture growth was followed by flow cytometry
with propidium iodide as a viability marker. IC50 values
were calculated by linear regression analysis of the rela-
tion between drug concentration and cell viability.
Cytotoxicity assay
The effect of prodigiosin on Vero cells and human lym-
phocytes was evaluated through flow cytometry and
microscopy counting, respectively. First, 2.5 × 10
6 cells
were incubated in RPMI 1640, 2% FCS supplemented
medium for 24 h at 37°C with 5% CO2 to secure their
adherence. Cells were then treated with prodigiosin con-
centrations ranging from 0.625 μMt o5 0μMf o r2 4h .
After treatment, the supernatant and the dislodged
adherent cells were used to quantify the live cells by
propidium iodide staining. Cells treated with PBS or
DMSO 30% were used as negative and positive controls,
respectively. The cytotoxic assays for human lympho-
cytes were carried out using isolated lymphocytes by
Ficoll-Paque gradient from a volunteer [50]. A total of 2
×1 0
5 cells were cultivated in RPMI 1640, 10% FCS sup-
plemented medium for 48 h at 37°C with 5% CO2. Lym-
phocytes were treated with prodigiosin concentrations
ranging from 0.78 μMt o1 2μM for 24 h. After treat-
ment, the lymphocytes were used to quantify the live
cells by trypan blue staining. Lymphocytes treated with
PBS or H2O2 50 μMw e r eu s e da sn e g a t i v ea n dp o s i t i v e
controls, respectively.
Mitochondrial function assays
Oxygen uptake assay
T. cruzi epimastigotes were harvested by 500 × g centri-
fugation, washed twice, and suspended in 0.05 M
sodium phosphate and 0.107 M sodium chloride buffer,
pH 7.4. Respiration measurements were carried out
polarographically with a Clark no. 5331 electrode (Yel-
low Springs Instruments) in a 53 YSI model (Simpson
Electric Co) [51]. The chamber volume was 0.6 mL and
the temperature was 28°C. The amount of parasite used
was equivalent to 1 mg/mL of protein. To study the per-
formance of cellular respiration we used several concen-
trations of TTFA, KCN, or prodigiosin as treatments. In
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dehydrogenase (complex II), cytochrome c reductase
(complex III) and cytochrome c oxidase (complex IV),
we added succinate 5 mM, duroquinol 0.5 mM, and
TMPD 0.1 mM/ascorbate 10 mM, respectively, after
having added prodigiosin at concentrations from 0.287
μM to 5 mM. Oxygen uptake was then determined.
Values are expressed as mean ± SD for three indepen-
dent experiments.
Mitochondrial transmembrane potential (Ψm)
Parasites in LIT medium/10% FCS at 1.5 × 10
6 para-
sites/mL were treated with rotenone, TTFA, antimycin
A, KCN, or prodigiosin for 1 h. The treated parasites
were then incubated with 1uM tetramethylrhodamine
methyl ester perchlorate (TMRM, Sigma CAT# T5428)
and analyzed with a cytometer. TMRM loading was car-
ried out at 28°C in all treated and control parasites. The
u n c o u p l e rC C C P( 1 0 0u M )w a su s e da sap o s i t i v e
control.
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